Takeda, Lundbeck Announce FDA Approval of Brintellix for Treatment of Adults with MDD

Takeda Pharmaceutical Company Limited (OTC: TKPYY ) and H. Lundbeck A/S (OTC: HLUKF ) jointly announced Monday that the U.S. Food and Drug Administration (FDA) has approved Brintellix (vortioxetine) for the treatment of adults with major depressive disorder (MDD), a debilitating mental health illness affecting approximately 14 million